Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Pediatric inspired (BFM) protocol in adolescent and young adults (AYA) with acute lymphoblastic leukemia (ALL) in India: Real‑world treatment timelines and impact of delays on survival

View Full Paper
Ask AI
Bookmark
Share

Authors

ASAlok ShettyPKParathan KarunakaranTNThejeswar Nakka

Discussion

Loading...

Member takes

Overview

Observational analysis found treatment delays reduced survival in AYA with acute lymphoblastic leukemia, indicating the need for timely regimens.

Key Points

  • Survival is negatively affected by treatment delays in adolescent and young adults with acute lymphoblastic leukemia.
  • Event-free survival was significantly lower for patients with treatment delays exceeding established cutoffs.
  • Analysis of clinical data from the INwARD registry revealed key timelines for treatment phases impacting outcomes.
  • These findings highlight the importance of prompt initiation of treatment in improving survival rates for AYA ALL patients.

Cite This Study

Shetty et al. (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e300https://doi.org/10.1182/blood-2025-8049
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world data of adolescents and young adults with acute lymphoblastic leukemia treated with a modified GMALL protocol in India: Treatment outcomes and challenges2025
  2. 2Overall survival in patients with acute lymphoblastic leukemia in the aya population, treated with modified pediatric chemotherapeutic schemes, a real-life study2025
  3. 3Outcomes of adolescent and young adult patients with AML treated on adult versus pediatric protocols2025
  4. 4Prognostic factors influencing relapse and survival of childhood acute lymphoblastic leukemia with the ALL-BFM IC 2009 protocol2025
  5. 5Effectiveness and prognostic impact of BMI, MRD and CNS involvement in AYA patients with Philadelphia-negative ALL treated using the AYA-15 protocol: Real-world from a tertiary center in the middle east2025